Abstract:Abstract Despite therapeutic advances in the past decade, head and neck squamous cell carcinoma (HNSCC) continues to be a major public health concern. Although recent studies of human cancer genomes identified remarkable complexity of genomic alterations in HNSCC, surprisingly, most aberrations have fallen within key driver signaling pathways. Among them, PI3K/AKT/mTOR pathway is most frequently activated in over 80% of the HNSCC patients. We showed that the majority of HNSCC lesions exhibit high levels of phosphorylated ribosomal S6 protein (pS6), key downstream target of the AKT-mTOR pathway, and that inhibition of mTOR by the use of rapamycin causes a rapid decrease in the level of pS6 and the apoptotic death of HNSCC tumor xenografts, thereby causing tumor regression. Our initial studies identified the AKT-mTOR pathway as a potential therapeutic target for HNSCC and provided strong rational to initiate multiple clinical trials. Indeed, inhibitors of PI3K/AKT/mTOR block mTOR activity and exert a beneficial response in HNSCC patients. However, therapeutic resistance was evidenced in several trials, which might be due to the activation of adaptive survival signaling in tumor cells. To explore the therapeutic option that can overcome the resistance, we performed a synthetic lethality screen in HNSCC cell lines using shRNA libraries. We found that multiple molecules involved in ERK pathway were highly represented. Furthermore, treating HNSCC cell lines harboring activated mTOR with small molecule inhibitors that target PI3K/AKT/mTOR pathway can sequentially induce ERK activation, which is consistent with the findings observed in numerous clinical trials. We demonstrated that co-targeting mTOR and ERK using trametinib, a MEK1/2 inhibitor or cetuximab, an EGFR monoclonal antibody, exhibited the synergistic effect by sensitizing HNSCC to priming with the mTOR inhibitor. Specifically, mTOR-ERK co-targeting prevented the growth of HNSCC tumor xenografts by decreasing cell proliferation, reducing lymphangiogenesis and activating apoptosis. In addition, we have recently used a phosphoproteomics approach to identify the molecular mechanisms of ERK feedback activation caused by PI3K/AKT/mTOR inhibition. Overall, our promising findings from these preclinical studies suggest that the use of mTOR-ERK co-targeting strategies may provide the novel alternative approach to achieve durable responses (cure) in HNSCC cancer patients. Citation Format: Zhiyong Wang, Esteban Delgado, Kosuke Yamaguchi, Ramiro Iglesias-Bartolomé, Panomwat Amornphimoltham, Alfredo Molinolo, Qianming Chen, J.Silvio Gutkind. mTOR-ERK co-targeting strategies for head and neck cancer therapy [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 351. doi:10.1158/1538-7445.AM2017-351

CGP57380 Enhances Efficacy of RAD001 in Non-Small Cell Lung Cancer Through Abrogating Mtor Inhibition-Induced Phosphorylation of Eif4e and Activating Mitochondrial Apoptotic Pathway.

Mnk1 Inhibitor Cgp57380 Overcomes The Activation Of Eif4e Induced By Mtorc1 Inhibitor: The Mechanism Of Synergic Killing On T-All Cells

[RAD001 Reverses Radio-Resistance and Exerts Synergistic Tumor Inhibition with 5-Fluorouracil].

Concomitant targeting of the mTOR/MAPK pathways: novel therapeutic strategy in subsets of -altered non-small cell lung cancer.

Combinations of Mtorc1 Inhibitor RAD001 with Gemcitabine and Paclitaxel for Treating Non-Hodgkin Lymphoma.

Lack of Compensatory Pakt Activation and Eif4e Phosphorylation of Lymphoma Cells Towards Mtor Inhibitor, RAD001

The Combination of RAD001 and NVP-BEZ235 Exerts Synergistic Anticancer Activity Against Non-Small Cell Lung Cancer in Vitro and in Vivo

Rapamycin And Trametinib: A Rational Combination For Treatment Of Nsclc

Combined Inhibition Of The Egfr And Mtor Pathways In Egfr Wild-Type Non-Small Cell Lung Cancer Cell Lines With Different Genetic Backgrounds

Abstract 2333: Modulation of Bax and Mtor for Cancer Therapeutics

Prediction and Optimization of the Therapeutic Effect of Mtor Inhibitors in Aggressive B-Cell Lymphomas

Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC Via Promoting Autophagy.

Synergistic Effects Between Mtor Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells

Mtor Inhibitor Rad001 (Everolimus) Induces Apoptotic, Not Autophagic Cell Death, In Human Nasopharyngeal Carcinoma Cells

Synergistic Antitumor Activity of Rapamycin and EF24 Via Increasing ROS for the Treatment of Gastric Cancer.

Rapamycin Enhances The Anti-Cancer Effect Of Dasatinib By Suppressing Src/Pi3k/Mtor Pathway In Nsclc Cells

The Mtor Kinase Inhibitors, CC214-1 and CC214-2, Preferentially Block the Growth of EGFRvIII-activated Glioblastomas.

Combined Treatment Of Mitoxantrone Sensitizes Breast Cancer Cells To Rapalogs Through Blocking Eef-2k-Mediated Activation Of Akt And Autophagy

Abstract 351: Mtor-Erk Co-Targeting Strategies for Head and Neck Cancer Therapy

Activated mammalian target of rapamycin is a potential therapeutic target in gastric cancer

Data from A Novel Mtorc1/2 Inhibitor (MTI-31) Inhibits Tumor Growth, Epithelial–Mesenchymal Transition, Metastases, and Improves Antitumor Immunity in Preclinical Models of Lung Cancer